[IMCAS Asia 2026 Special ④ | Symposium] LASEROPTEK Shares Clinical Experience with HELIOS 785 PICO 'melaKlear' for Melasma Treatment in Bangkok
On the eve of IMCAS Asia 2026 (June 19–21, Bangkok), two clinicians from Korea and Indonesia shared their clinical experience treating melasma with the HELIOS 785 PICO (marketed internationally as ‘melaKlear’) at the LASEROPTEK Partners Meeting (LPM) in Bangkok 2026. Melasma is a challenging pigmentary disorder — recurrence is common, and the risk of post-inflammatory hyperpigmentation (PIH) rises in darker skin. The 785 nm picosecond wavelength was presented as offering a clinically useful balance between melanin absorption and penetration relative to 1064 nm and 532 nm. Dr. Seokbae Seo of SeoASong Dermatology (Seoul, Korea) emphasized tailoring treatment to each patient’s skin type and lesion rather than raising energy, while Dr. Chandra Permana of ERHA Clinic (Jember, Indonesia) presented a single-session protocol combined with topical therapy, aimed at achieving an early, visible improvement. LASEROPTEK CEO Changjin Lee also emphasized the company’s identity as a laser-specialist manufacturer and introduced its new vascular laser, VASCURA 589.
#MedicalAestheticNews #LASEROPTEK #HELIOS785PICO #DrSeokbaeSeo #SeoASongDermatology #DrChandraPermana #ERHAClinic
★ Article Link: https://www.medicalaestheticnews.com/news/articleView.html?idxno=20092




Comments
Post a Comment